Gao S, et al. - Researchers analyzed relevant articles in the PubMed database up to April 2018, to determine the association between fibroblast growth factor 23 (FGF23) and risk of all-cause mortality and cardiovascular disease (CVD) events in hemodialysis patients. They performed a meta-analysis of 7 articles, using the Revman 5.3 software. All the studies mentioned mortality in hemodialysis patients and 3 reported cardiovascular events in hemodialysis patients. They focused on the association between C-terminal FGF23 (cFGF23) and intact-FGF23 (iFGF23) and death and cardiovascular events in hemodialysis patients because it was possible to detect cFGF23 and iFGF23 with the current reagent. In this study, findings revealed a positive association of elevated serum FGF23 levels with all-cause mortality and cardiovascular events in hemodialysis patients. A 14 or 39% increase in all-cause mortality and a 21% increased risk of cardiovascular events were reported in relation to elevated serum FGF23 levels.